Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of LY2835219 for Patients With Previously Treated Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer

NCT02102490 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT02102490
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02102490 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of LY2835219 for Patients With Previously Treated Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer
Lead sponsor
Eli Lilly and Company
Phase
Phase 2
Overall status
Completed
Start date
June 10, 2014
Completion date
October 22, 2018
Enrollment
132 (actual)
Sites
36

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic breast cancer